MSLE Earnings Date: Nov 13, 2026 (Estimated) — Satellos Bioscience Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MSLE's next earnings date?
Satellos Bioscience Inc. (MSLE) is expected to report earnings on Friday, November 13, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.60.
How did MSLE do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Satellos Bioscience Inc. posted EPS of -$0.56 versus the -$0.38 estimate, a miss of 5.7%. Revenue was $0. The stock's 1-day post-earnings move was -2.1%.
How much does MSLE stock move after earnings?
MSLE beat EPS estimates in 0 of its last 1 reported quarter. Over the last 2 reports the stock moved an average of 2.2% (up or down) in the day after earnings.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.38 | -0.56 | -5.66% | $0 | ❌ Miss | -2.14% | +3.72% | -0.31% |
| 2026-05-15 | Q1 2026 | — | -0.53 | — | $0 | — | -2.23% | -0.42% | -19.80% |
Showing last 2 quarters.